There is no set time limit for semaglutide. The FDA approved Wegovy (the weight management version) as a long-term medication, meaning it’s designed to be taken indefinitely, much like drugs for high blood pressure or cholesterol. The longest clinical trials have tracked patients on continuous treatment for about two years, and the real-world question of “how long” often comes down to tolerability, cost, and whether you and your doctor see ongoing benefit.
Why It’s Classified as a Long-Term Medication
The FDA’s approval language for Wegovy specifically states it is “indicated to reduce excess body weight and maintain weight reduction long-term.” That phrasing is deliberate. Semaglutide isn’t approved as a short course you take for six months and stop. It’s categorized alongside other chronic medications because the condition it treats, obesity, is itself chronic.
The biological reason is straightforward. Your body actively resists weight loss. After you lose weight, hormonal and metabolic shifts kick in that increase appetite, reduce the calories you burn at rest, and drive food preoccupation. These compensatory mechanisms persist for at least a year after the initial weight loss, and likely longer. Semaglutide works by mimicking a gut hormone that suppresses appetite and slows digestion. When you stop taking it, those protective effects disappear, and your body’s weight-regain signals take over unopposed.
What Happens When You Stop
The data on this point is consistent and sobering. A 2025 systematic review in The BMJ found that people taking newer, more effective versions of these medications (semaglutide and tirzepatide) regained weight at a rate of about 0.8 kg (roughly 1.8 pounds) per month after stopping. Within the first year off medication, the average regain was nearly 10 kg (about 22 pounds). The analysis projected a return to baseline weight, meaning all lost weight regained, within approximately 1.5 years of stopping treatment.
Earlier data from the STEP 1 trial told a similar story: participants regained roughly two-thirds of their prior weight loss within a year of discontinuation. This isn’t a failure of willpower. It reflects the same hormonal rebound that makes sustained weight loss so difficult regardless of the method.
How Long the Safety Data Actually Covers
The longest completed weight management trial, STEP 5, followed patients on semaglutide 2.4 mg for 104 weeks (two years) with a short follow-up period extending to week 111. Adverse events were tracked throughout, and the safety profile at two years was consistent with what was seen in shorter trials. The SELECT cardiovascular outcomes trial ran even longer, up to five years, though its primary focus was heart events rather than weight.
This means there is solid safety data for at least two years of continuous use in controlled settings, with additional years of cardiovascular monitoring. What we don’t have yet is large-scale data tracking ten or twenty years of uninterrupted use. That’s typical for medications approved in recent years, and the safety picture will continue to fill in over time.
Muscle Loss Over Time
One concern that grows with longer use is muscle loss. In the STEP 1 trial, about 45% of the total weight lost came from lean mass rather than fat. That’s a higher ratio than what most people expect when they think about weight loss. Over months and years, losing muscle can affect strength, metabolism, and mobility, particularly in older adults.
This is one reason many providers strongly recommend resistance training for anyone on semaglutide, especially those planning to stay on it long-term. Adequate protein intake also helps preserve muscle. These aren’t optional add-ons; they’re an important part of making extended treatment sustainable and healthy.
The Insurance Reality
Even though the medication is approved for indefinite use, insurance coverage often works in shorter windows. A representative policy from Cigna, for example, approves initial therapy for seven months. After that, renewal requires demonstrating at least 5% weight loss from baseline, and coverage is then extended for one year at a time. Each renewal cycle requires meeting that threshold again.
This creates a practical ceiling for many patients. If your weight loss plateaus below 5%, or if you experience a coverage gap, you may face interruptions regardless of medical need. For people paying out of pocket, the monthly cost (often $1,000 or more without insurance) becomes the primary limiting factor.
How Many People Actually Stay On It
Clinical trials report medication continuation rates above 90%, but real-world numbers look very different. An analysis of commercially insured adults without diabetes found that only 36% of Wegovy users were still taking the medication at the one-year mark. Adherence (taking it consistently enough to be effective) was even lower, at about 31.5%.
The gap between trial data and real life reflects a mix of factors: side effects, cost, supply shortages, insurance denials, and personal choice. The most common side effects, nausea, vomiting, and diarrhea, are worst during the dose escalation phase (the first 16 to 20 weeks as your dose gradually increases). Many people who discontinue do so during this window. Those who tolerate the ramp-up and reach the maintenance dose of 2.4 mg (or 1.7 mg if the full dose causes too many side effects) are more likely to stay on long-term.
What Long-Term Use Looks Like in Practice
If you and your provider decide to continue semaglutide indefinitely, the experience typically settles into a routine. After the initial dose escalation, you take a weekly injection at a stable dose. The appetite-suppressing effects remain active as long as you’re on the medication, though some people report that the intensity of appetite reduction diminishes somewhat over time.
There is no standard protocol for stepping down to a lower dose once you’ve reached your weight goal. The FDA labeling allows for a maintenance dose of either 2.4 mg or 1.7 mg weekly, but there’s no formal “transition to weight stability” phase. In practice, some providers experiment with reduced dosing to see if a lower amount is enough to prevent regain while minimizing side effects and cost. This is an area where clinical practice is still evolving, and decisions are made case by case.
The bottom line: semaglutide is designed and approved for use as long as it’s helping and you’re tolerating it. Most of the evidence points toward ongoing treatment being necessary to maintain results, since the weight typically comes back when the medication stops. How long you personally stay on it will depend on your response, your side effects, and whether you can maintain consistent access.